Table 1.
Baseline characteristics of men with PCa on ADT and the matched comparison cohort of PCa‐free men in Prostate Cancer Data Base 3.0
| PCa Free Cohort | All men with PCa | AA | GnRH | Orchiectomy | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | 167,205 | 34,031 | 9,143 | 21,874 | 3,014 | |||||
| Mean Follow up time (SD) | ||||||||||
| 4.2 | (2.5) | 3.5 | (2.4) | 3.6 | (2.3) | 3.5 | (2.4) | 3.1 | (2.4) | |
| Age | ||||||||||
| Mean age at diagnosis (SD) | 74.8 | (8.5) | 74.4 | (8.4) | 71.2 | (8.0) | 75.2 | (8.3) | 78.4 | (7.3) |
| <65 | 23183 | (13.9) | 4908 | (14.4) | 2119 | (23.2) | 2623 | (12.0) | 166 | (5.5) |
| 65‐74 | 55348 | (33.1) | 11806 | (34.7) | 3893 | (42.6) | 7247 | (33.1) | 666 | (22.1) |
| 75‐84 | 70809 | (42.3) | 14136 | (41.5) | 2829 | (30.9) | 9655 | (44.1) | 1652 | (54.8) |
| 85+ | 17865 | (10.7) | 3181 | (9.3) | 302 | (3.3) | 2349 | (10.7) | 530 | (17.6) |
| Age at start of ADT | ||||||||||
| <65 | ‐ | ‐ | 3592 | (10.6) | 1189 | (13.0) | 2254 | (10.3) | 149 | (4.9) |
| 65‐74 | ‐ | ‐ | 10849 | (31.9) | 3641 | (39.8) | 6596 | (30.2) | 612 | (20.3) |
| 75‐84 | ‐ | ‐ | 15493 | (45.5) | 3766 | (41.2) | 10059 | (46.0) | 1668 | (55.3) |
| 85+ | ‐ | ‐ | 4097 | (12.0) | 547 | (6.0) | 2965 | (13.6) | 585 | (19.4) |
| Entry into PCBaSe cohort/Year of PCa diagnosis | ||||||||||
| 1997‐2001 | 17889 | (10.7) | 5389 | (15.8) | 1145 | (12.5) | 3687 | (16.9) | 557 | (18.5) |
| 2002‐2005 | 49375 | (29.5) | 11281 | (33.1) | 2738 | (29.9) | 7446 | (34.0) | 1097 | (36.4) |
| 2006‐2009 | 64085 | (38.3) | 11567 | (34.0) | 3438 | (37.6) | 7161 | (32.7) | 968 | (32.1) |
| 2010‐2012 | 35856 | (21.4) | 5794 | (17.0) | 1822 | (19.9) | 3580 | (16.4) | 392 | (13.0) |
| CCI | ||||||||||
| 0 | 110713 | (66.2) | 22328 | (65.6) | 6271 | (68.6) | 14143 | (64.7) | 1914 | (63.5) |
| 1 | 29651 | (17.7) | 6247 | (18.4) | 1587 | (17.4) | 4048 | (18.5) | 612 | (20.3) |
| 2 | 15948 | (9.5) | 3309 | (9.7) | 793 | (8.7) | 2215 | (10.1) | 301 | (10.0) |
| 3+ | 10893 | (6.5) | 2147 | (6.3) | 492 | (5.4) | 1468 | (6.7) | 187 | (6.2) |
| Education Status | ||||||||||
| Low | 78732 | (47.1) | 16239 | (47.7) | 3559 | (38.9) | 10898 | (49.8) | 1782 | (59.1) |
| Middle | 56051 | (33.5) | 11579 | (34.0) | 3422 | (37.4) | 7252 | (33.2) | 905 | (30.0) |
| High | 29171 | (17.4) | 5771 | (17.0) | 2091 | (22.9) | 3403 | (15.6) | 277 | (9.2) |
| Missing | 3251 | (1.9) | 442 | (1.3) | 71 | (0.8) | 321 | (1.5) | 50 | (1.7) |
| PCa risk category | ||||||||||
| No PCa | 167205 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| 1. Low risk | ‐ | ‐ | 2334 | (6.9) | 1180 | (12.9) | 1068 | (4.9) | 86 | (2.9) |
| 2. Intermediate risk | ‐ | ‐ | 6021 | (17.7) | 2819 | (30.8) | 2929 | (13.4) | 273 | (9.1) |
| 3. High risk | ‐ | ‐ | 11775 | (34.6) | 3469 | (37.9) | 7410 | (33.9) | 896 | (29.7) |
| 4. Regionally metastatic | ‐ | ‐ | 4745 | (13.9) | 962 | (10.5) | 3354 | (15.3) | 429 | (14.2) |
| 5. Distant metastases | ‐ | ‐ | 8850 | (26.0) | 591 | (6.5) | 6956 | (31.8) | 1303 | (43.2) |
| 6. Missing data | ‐ | ‐ | 306 | (0.9) | 122 | (1.3) | 157 | (0.7) | 27 | (0.9) |
| Primary Treatment | ||||||||||
| No PCa | 167205 | (100.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) | 0 | (0.0) |
| ADT | ‐ | ‐ | 24815 | (72.9) | 4113 | (45.0) | 17972 | (82.2) | 2730 | (90.6) |
| Curative treatment | ‐ | ‐ | 4352 | (12.8) | 2887 | (31.6) | 1402 | (6.4) | 63 | (2.1) |
| Deferred treatment | ‐ | ‐ | 4864 | (14.3) | 2143 | (23.4) | 2500 | (11.4) | 221 | (7.3) |